MX351626B - Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata. - Google Patents

Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.

Info

Publication number
MX351626B
MX351626B MX2014009283A MX2014009283A MX351626B MX 351626 B MX351626 B MX 351626B MX 2014009283 A MX2014009283 A MX 2014009283A MX 2014009283 A MX2014009283 A MX 2014009283A MX 351626 B MX351626 B MX 351626B
Authority
MX
Mexico
Prior art keywords
prostate cancer
test
gene expression
expression profile
determining prognosis
Prior art date
Application number
MX2014009283A
Other languages
English (en)
Other versions
MX2014009283A (es
Inventor
Maddala Tara
J Pelham Robert
Crager Michael
Shak Steve
Lee Mark
Novotny William
Cherbavaz Diana
L Millward Carl
Knezevic Dejan
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Publication of MX2014009283A publication Critical patent/MX2014009283A/es
Publication of MX351626B publication Critical patent/MX351626B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Complex Calculations (AREA)

Abstract

La presente invención se refiere a ensayos moleculares basados en algoritmo que implica en la medición de los niveles de expresión de los genes, o sus genes co-expresados, de una muestra biológica obtenida de un paciente con cáncer de próstata. Los genes se pueden agrupar en subconjuntos de genes funcionales para calcular un registro cuantitativo útil para predecir una probabilidad de un resultado clínico para un paciente con cáncer de próstata.
MX2014009283A 2012-01-31 2013-01-28 Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata. MX351626B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261593106P 2012-01-31 2012-01-31
US201261672679P 2012-07-17 2012-07-17
US201261713734P 2012-10-15 2012-10-15
PCT/US2013/023409 WO2013116144A1 (en) 2012-01-31 2013-01-28 Gene expression profile algorithm and test for determining prognosis of prostate cancer

Publications (2)

Publication Number Publication Date
MX2014009283A MX2014009283A (es) 2014-09-11
MX351626B true MX351626B (es) 2017-10-23

Family

ID=48870540

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2014009283A MX351626B (es) 2012-01-31 2013-01-28 Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
MX2017013491A MX366164B (es) 2012-01-31 2013-01-28 Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
MX2019007814A MX2019007814A (es) 2012-01-31 2014-07-31 Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2017013491A MX366164B (es) 2012-01-31 2013-01-28 Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
MX2019007814A MX2019007814A (es) 2012-01-31 2014-07-31 Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.

Country Status (14)

Country Link
US (3) US8725426B2 (es)
EP (3) EP3739595A3 (es)
JP (3) JP6351112B2 (es)
AU (3) AU2013215448B2 (es)
CA (1) CA2863040C (es)
CO (1) CO7051010A2 (es)
DK (1) DK3179393T3 (es)
ES (1) ES2812105T3 (es)
HK (1) HK1201881A1 (es)
IL (3) IL233709A (es)
MX (3) MX351626B (es)
NZ (2) NZ627887A (es)
SG (3) SG11201404390WA (es)
WO (1) WO2013116144A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8725426B2 (en) * 2012-01-31 2014-05-13 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer
ES2945036T3 (es) 2012-08-16 2023-06-28 Veracyte Sd Inc Pronóstico del cáncer de próstata mediante biomarcadores
GB201322034D0 (en) 2013-12-12 2014-01-29 Almac Diagnostics Ltd Prostate cancer classification
WO2015094854A1 (en) * 2013-12-18 2015-06-25 Pacific Biosciences Inc. Iterative clustering of sequence reads for error correction
CN103695560B (zh) * 2014-01-09 2016-09-14 上海交通大学医学院附属瑞金医院 Ppp1r12a基因在结直肠癌化疗疗效判断和检测试剂盒中的应用
AU2015206336B2 (en) * 2014-01-16 2020-01-23 Illumina, Inc. Gene expression panel for prognosis of prostate cancer recurrence
WO2015131177A1 (en) * 2014-02-28 2015-09-03 The Johns Hopkins University Genes encoding secreted proteins which identify clinically significant prostate cancer
EP3143160B1 (en) * 2014-05-13 2019-11-06 Myriad Genetics, Inc. Gene signatures for cancer prognosis
EP3210144B1 (en) 2014-10-24 2020-10-21 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
ES2857953T3 (es) 2014-10-24 2021-09-29 Koninklijke Philips Nv Pronóstico médico y predicción de la respuesta al tratamiento usando las actividades de múltiples rutas de señalización celular
US10016159B2 (en) 2014-10-24 2018-07-10 Koninklijke Philips N.V. Determination of TGF-β pathway activity using unique combination of target genes
CN104880565A (zh) * 2015-05-04 2015-09-02 贵州省人民医院 Zfp36前列腺癌预后诊断的检测试剂及其试剂盒
DK3303618T3 (da) * 2015-05-29 2019-12-16 Koninklijke Philips Nv Fremgangsmåder til prognose af prostatacancer
WO2016193110A1 (en) * 2015-05-29 2016-12-08 Koninklijke Philips N.V. Methods of prostate cancer prognosis
JP6202659B2 (ja) * 2015-07-01 2017-09-27 学校法人慶應義塾 癌組織の不均一性マーカー及びその使用
DK3334837T3 (da) 2015-08-14 2021-02-15 Koninklijke Philips Nv Vurdering af nfkb-cellulær signaleringsvejaktivitet under anvendelse af matematisk modellering af målgenekspression
CA2996426A1 (en) 2015-10-05 2017-04-13 Cedars-Sinai Medical Center Method of classifying and diagnosing cancer
EP3405583B1 (en) * 2016-01-20 2024-04-03 Dana-Farber Cancer Institute, Inc. Compositions and methods for screening and identifying clinically aggressive prostate cancer
DK3270163T3 (en) * 2016-07-15 2018-11-19 Proteomedix Ag PROCEDURE FOR DETECTING PROTEINS IN HUMAN SAMPLES AND APPLICATIONS OF SUCH PROCEDURES
AU2017315425B2 (en) 2016-08-24 2023-11-09 The Regents Of The University Of Michigan Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
US11586674B2 (en) * 2016-12-28 2023-02-21 Khalifa University of Science and Technology Methods and systems for searching
CA3049844C (en) * 2017-02-13 2022-06-28 Genomic Health, Inc. Algorithms and methods for assessing late clinical endpoints in prostate cancer
CA3055925A1 (en) * 2017-03-09 2018-09-13 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
US12497660B2 (en) 2017-08-04 2025-12-16 Veracyte SD, Inc. Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy
EP3461916A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat3 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3461915A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression
WO2019082118A1 (en) * 2017-10-27 2019-05-02 King Abdullah University Of Science And Technology GRAPHIC BASED CONSTANT COLUMN DOUBLE CLASSIFICATION DEVICE AND METHOD FOR MINIMIZING GROWTH PHENOTYPE DATA
EP3502279A1 (en) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3502280A1 (en) 2017-12-21 2019-06-26 Koninklijke Philips N.V. Pre-surgical risk stratification based on pde4d7 expression and pre-surgical clinical variables
US12123058B2 (en) 2018-01-25 2024-10-22 Sorbonne Universite Molecular signature and use thereof for the identification of indolent prostate cancer
WO2019165021A1 (en) * 2018-02-22 2019-08-29 Liquid Biopsy Research LLC Methods for prostate cancer detection and treatment
CA3003032A1 (en) * 2018-04-27 2019-10-27 Nanostics Inc. Methods of diagnosing disease using microflow cytometry
CN109001467A (zh) * 2018-07-20 2018-12-14 贵州省人民医院 一种用于前列腺癌的基因联合预后检测试剂及其制备方法
GB201816820D0 (en) * 2018-10-16 2018-11-28 Univ York Diagnostic method
EP3874274B1 (en) 2018-10-31 2024-01-03 Regents of the University of Minnesota Methods for predicting a response to bevacizumab or platinum-based chemotherapy or both in patients with ovarian cancer
EP4013494A1 (en) 2019-08-12 2022-06-22 Regeneron Pharmaceuticals, Inc. Macrophage stimulating 1 receptor (mst1r) variants and uses thereof
CN115398548A (zh) * 2020-02-06 2022-11-25 昂科霍斯特公司 疗法响应的机器学习预测
EP3901288A1 (en) * 2020-04-20 2021-10-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Multi-gene expression assay for prostate carcinoma

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2339200B (en) 1998-06-06 2001-09-12 Genostic Pharma Ltd Genostics
AU4158799A (en) 1998-06-06 1999-12-30 Genostic Pharma Limited Probes used for genetic filing
WO2000040749A2 (en) 1999-01-06 2000-07-13 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
FI990382A0 (fi) 1999-02-23 1999-02-23 Arctic Partners Oy Ab Uusi diagnostinen menetelmä
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
NZ520095A (en) 2000-01-13 2004-05-28 Genentech Inc Novel Stra6 polypeptides, nucleic acids, antibodies, compositions and methods of treatments for inhibiting tumor cell growth
AU2002214576A1 (en) 2000-10-13 2002-04-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genes related to development of refractory prostate cancer
WO2002074156A2 (en) 2001-02-02 2002-09-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20060088823A1 (en) 2001-03-29 2006-04-27 Brian Haab Microarray gene expression profiling in clear cell renal cell carcinoma : prognosis and drug target identification
WO2003009814A2 (en) 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
US20100297657A1 (en) 2001-08-02 2010-11-25 The Regents Of The University Of Michigan Expression profile of prostate cancer
JP5236856B2 (ja) 2001-11-09 2013-07-17 ライフ テクノロジーズ コーポレーション 遺伝子発現プロファイルを用いる病気の同定、観測及び治療及び生物学的状態の同定
AU2002357747A1 (en) 2001-12-10 2003-06-23 Millennium Pharmaceuticals Inc. Novel genes encoding colon cancer antigens
US6949342B2 (en) * 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
JP2005519606A (ja) 2002-03-14 2005-07-07 エグゾニ・テラピューティック・ソシエテ・アノニム ヒトカリクレイン−２及びカリクレイン−３のバリアント並びにそれらの使用
AUPS187002A0 (en) 2002-04-22 2002-05-30 Queensland University Of Technology Condition-specific molecules and uses therefor
CA2498418A1 (en) 2002-09-10 2004-03-25 Guennadi V. Glinskii Gene segregation and biological sample classification methods
WO2004108896A2 (en) 2003-06-03 2004-12-16 The Board Of Trustees Of The University Of Arkansas Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
ES2905579T3 (es) 2003-07-10 2022-04-11 Genomic Health Inc Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
WO2005007830A2 (en) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
JP2007507204A (ja) 2003-07-29 2007-03-29 ブリストル−マイヤーズ　スクイブ　カンパニー サイクリン依存性キナーゼモデュレーションのバイオマーカー
WO2005076005A2 (en) 2004-01-30 2005-08-18 Medizinische Universität Wien A method for classifying a tumor cell sample based upon differential expression of at least two genes
JP2005211023A (ja) 2004-01-30 2005-08-11 Hayashibara Biochem Lab Inc 腎細胞癌の転移若しくは再発の可能性を予測する方法
US20070224596A1 (en) 2004-04-09 2007-09-27 Mariana Nacht Compositions and methods for the modifying hypoxia induced gene regulation
EP1737980A2 (en) 2004-04-09 2007-01-03 Fondazione IRCCS Istituto Nazionale dei Tumori Gene expression markers for predicting response to chemotherapy
AU2005245815B2 (en) 2004-05-07 2011-06-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
WO2005117943A2 (en) 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Biomarkers for monitoring inhibition of impdh pathway
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
CA2576624A1 (en) 2004-08-13 2006-03-16 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
US7666595B2 (en) 2005-02-25 2010-02-23 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
WO2006110264A2 (en) 2005-03-16 2006-10-19 Sidney Kimmel Cancer Center Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures
CA2608359A1 (en) 2005-05-13 2006-11-23 Duke University Gene expression signatures for oncogenic pathway deregulation
ES2624863T3 (es) 2005-06-08 2017-07-17 Millennium Pharmaceuticals, Inc. Métodos para identificación, evaluación, y tratamiento de pacientes con terapia de cáncer
US20070099209A1 (en) 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006138275A2 (en) 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CA2620936A1 (en) 2005-09-01 2007-03-08 Precision Therapeutics, Inc. Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics
US7718369B2 (en) 2005-09-12 2010-05-18 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
JP5984324B2 (ja) 2005-12-01 2016-09-06 メディカル プログノシス インスティテュート エー／エス 治療反応のバイオマーカーを同定するための方法および装置、ならびに治療効果を推定するためのその使用
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
US20090215054A1 (en) 2005-12-13 2009-08-27 Carter Scott L Prognosis indicators for solid human tumors
NZ593224A (en) 2006-01-11 2012-10-26 Genomic Health Inc Gene expression markers (fap) for colorectal cancer prognosis
ES2300176B1 (es) 2006-02-15 2009-05-01 Consejo Superior Investig. Cientificas Metodo para el diagnostico molecular de cancer de prostata, kit para implementar el metodo.
US7914988B1 (en) 2006-03-31 2011-03-29 Illumina, Inc. Gene expression profiles to predict relapse of prostate cancer
US7888019B2 (en) 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
EP2029020A4 (en) 2006-06-22 2010-04-21 Wisconsin Alumni Res Found USE OF STROMA COLLAGEN IN THE DIAGNOSIS AND CHARACTERIZATION OF BREAST CANCER
WO2008067065A2 (en) 2006-10-19 2008-06-05 Shiv Srivastava Methods, kits, and systems for diagnosing and prognosing prostate cancer using secreted biomarkers
JP2010509598A (ja) * 2006-11-13 2010-03-25 ライフ テクノロジーズ コーポレーション 前立腺癌バイオマーカーを検出するための方法およびキット
US20090258795A1 (en) 2007-03-15 2009-10-15 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
US8835480B2 (en) * 2007-04-23 2014-09-16 California Institute Of Technology Inhibitors for steroid response elements and related methods
US20090123439A1 (en) 2007-11-09 2009-05-14 The Jackson Laboratory Diagnostic and prognosis methods for cancer stem cells
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
EP2806054A1 (en) 2008-05-28 2014-11-26 Genomedx Biosciences Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US20090298082A1 (en) * 2008-05-30 2009-12-03 Klee George G Biomarker panels for predicting prostate cancer outcomes
AU2009270851A1 (en) 2008-07-16 2010-01-21 Dana-Farber Cancer Institute, Inc. Signatures and PCDETERMINANTS associated with prostate cancer and methods of use thereof
US20110230361A1 (en) 2008-11-14 2011-09-22 Emory University Prostate cancer biomarkers to predict recurrence and metastatic potential
CN102308212A (zh) 2008-12-04 2012-01-04 加利福尼亚大学董事会 用于确定前列腺癌诊断和预后的材料和方法
ES2991436T3 (es) 2009-01-07 2024-12-03 Myriad Genetics Inc Biomarcadores de cáncer
US8765383B2 (en) 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
US20100303795A1 (en) 2009-05-27 2010-12-02 Soerensen Karina Dalsgaard Marker of prostate cancer
US10095829B2 (en) 2009-07-08 2018-10-09 Worldwide Innovative Network Computer implemented methods of treating lung cancer
JP5964752B2 (ja) * 2009-11-23 2016-08-03 ジェノミック ヘルス， インコーポレイテッド 癌の臨床転帰を予測する方法
MX375138B (es) 2010-01-11 2025-03-06 Genomic Health Inc Método para usar expresión génica para determinar la probabilidad de un desenlace clínico de cáncer renal.
EP2913405B1 (en) * 2010-07-27 2016-11-09 Genomic Health, Inc. Method for using gene expression to determine prognosis of prostate cancer
US8725426B2 (en) * 2012-01-31 2014-05-13 Genomic Health, Inc. Gene expression profile algorithm and test for determining prognosis of prostate cancer

Also Published As

Publication number Publication date
IL254255B (en) 2018-11-29
JP6351112B2 (ja) 2018-07-04
IL254255A0 (en) 2017-10-31
WO2013116144A1 (en) 2013-08-08
MX2019007814A (es) 2019-09-05
AU2018201688B2 (en) 2020-02-27
US20130196321A1 (en) 2013-08-01
IL233709A (en) 2017-09-28
CA2863040C (en) 2022-04-19
SG10201605210PA (en) 2016-08-30
CO7051010A2 (es) 2014-09-10
EP3179393B1 (en) 2020-07-08
US11011252B1 (en) 2021-05-18
NZ627887A (en) 2016-08-26
AU2020202164A1 (en) 2020-04-16
EP3179393A2 (en) 2017-06-14
US20140303002A1 (en) 2014-10-09
AU2013215448B2 (en) 2018-01-04
IL233709A0 (en) 2014-09-30
SG11201404390WA (en) 2014-08-28
ES2812105T3 (es) 2021-03-16
JP2015511814A (ja) 2015-04-23
DK3179393T3 (da) 2020-07-27
IL262648A (en) 2018-12-31
EP3179393A3 (en) 2017-09-13
IL262648B (en) 2020-07-30
EP2809812A1 (en) 2014-12-10
AU2020202164B2 (en) 2022-02-10
MX2014009283A (es) 2014-09-11
EP3739595A3 (en) 2021-01-27
EP2809812A4 (en) 2016-01-27
SG10201912312YA (en) 2020-02-27
MX366164B (es) 2019-07-01
NZ722902A (en) 2017-12-22
JP2017113008A (ja) 2017-06-29
JP6908571B2 (ja) 2021-07-28
CA2863040A1 (en) 2013-08-08
JP2019013255A (ja) 2019-01-31
AU2018201688A1 (en) 2018-04-05
AU2013215448A1 (en) 2014-08-21
EP3739595A2 (en) 2020-11-18
HK1201881A1 (en) 2015-09-11
US8725426B2 (en) 2014-05-13

Similar Documents

Publication Publication Date Title
MX2019007814A (es) Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
MX2018011725A (es) Metodo para emplear expresion genica para determinar pronostico de cancer de prostata.
MX2019013953A (es) Metodo basado en expresion genica para clasificar pacientes con cancer de riñon de acuerdo al riesgo de recurrencia.
NZ705645A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
MX2011011571A (es) Algoritmo de perfil de expresion genica y prueba para probabilidad de recidiva de cancer colorrectal y respuesta a la quimioterapia.
NZ599194A (en) Methods to predict clinical outcome of cancer
WO2013153458A3 (en) Method for the prognosis and treatment of cancer metastasis
MX369628B (es) Genes nano46 y metodos para predecir el resultado del cancer de mama.
WO2012119113A3 (en) Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
WO2014144121A3 (en) Classification and actionability indices for lung cancer
HK1219763A1 (zh) 用於癌症预後的组合物和方法
EA201400117A1 (ru) Способы и нуклеиновые кислоты для определения прогноза у больных раком
BR112015022977A2 (pt) métodos para predição de risco de metástase em melanoma cutâneo
WO2012040500A3 (en) Direct blood assay for detection of circulating microrna in cancer patients
BR112017005421A2 (pt) método in vitro para prever se pacientes com câncer são propensos a reagir a um inibidor de receptor, kit e inibidor de egfr
BR112014023296A2 (pt) métodos para fazer tipagem de uma amostra de um paciente com hepatite b, para determinar se um paciente com hepatite b tem uma chance melhorada de um resultado positivo do tratamento da hepatite b, se um indivíduo tem uma predisposição genética para uma chance melhorada para um resultado positivo de tratamento da hepatite b, para identificar um gene, e para ensaiar quanto a presença de ácido nucleico, kit de partes ou arranjo ou microarranjo ou vetor, usos de pelo menos um polinucleotídeo isolado, de um kit de partes ou arranjo ou microarranjo ou vetor e de meios para determinar um nível de expressão de carnitina e/ou um derivado de carnitina
WO2010093907A3 (en) An assay for the detection of recurrence in breast cancer using the novel tumor suppressor dear1
PL401061A1 (pl) Nowe sondy do wykrywania bakterii z gatunku Acinetobacter baumannii, oligonukleotydowe startery, sposób oraz zestaw do analizy próbek medycznych i środowiskowych
MX2013013153A (es) La expresion de kiaa1456 predice la supervivencia en pacientes con cancer de colon.
WO2013190468A3 (en) Computer-based predictor for prostate cancer
WO2011133500A3 (en) Detection and analysis of epigenetic and genetic changes in tumor tissue
NZ610474A (en) Methods to predict clinical outcome of cancer
MY172477A (en) Stemness gene detection and methods thereof
RU2013120609A (ru) Способ косвенного определения чувствительности клеток рака легкого к цисплатину на основании уровней экспрессии маркерных генов и набор для его осуществления

Legal Events

Date Code Title Description
FG Grant or registration